ClinicalTrials.gg
CompletedNCT05492409Updated Jun 21, 2024

Study of the Safety and Immunogenicity of Long-term GNR-069 Therapy in ITP Patients

A Phase 3 interventional study of GNR-069 in Idiopathic Thrombocytopenic Purpura, sponsored by AO GENERIUM. Completed at 13 sites in Russian Federation. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-06-21.

Sponsored by AO GENERIUM · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled Mar 2022, registered Aug 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
160
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 6 under way, 2 of them phase 3. romiplostim · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
8th of 29
160 · median 62
Started
2022
with 1 other
Phase 3
13 of 29
1 open now
Registered
24th of 29
by date
Lead sponsor
2 of 29
AO GENERIUM

Among the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, this one is the 8th largest by enrollment, is one of 2 that started in 2022, is one of 13 in phase 3, and was the 24th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About romiplostim

romiplostim: first FDA approval 2008 (NPLATE), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 29 studies testing romiplostim in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

It is a phase III extension study to assess safety and immunogenicity of long-term therapy with GNR-069 in patients with idiopathic thrombocytopenic purpura

Read the detailed description

It is an extension study in patients with ITP who completed participation in RMP-ITP-III clinical trial.

The study will be conducted in three stages:

  • Transition visit - 1 day (transition of clinical trial participants from the RMP-ITP-III study to the RMP-ITP-III-X study);
  • Treatment period - minimum 26 weeks;
  • Follow-up period - 1 week. Patients will then be provided with the study therapy till the product market access with only safety data collection.
03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura

Keywords

  • Idiopathic thrombocytopenic purpura
  • ITP
  • Thrombocytopenia
  • Thrombocytopoiesis
  • Bleeding
  • Hemorrhagic syndrome
  • Petechial rash
  • Ecchymosis
  • Fc-peptide
  • Recombinant DNA technology
  • Thrombopoietin receptors
  • Platelet formation
  • Fc fragment of human immunoglobulin IgG 1
  • Low platelet count
  • ITP treatment
  • Platelets
  • Haemorrhage
  • Platelet destruction
  • Impaired thrombopoiesis
  • Megakaryocytes
  • Autoantibodies
  • Splenectomy
  • Cytotoxic
  • T cells
  • Thrombopoietin receptor agonists
  • Thrombopoietin receptor mimetic
  • TPO-RAs
  • romiplostim
  • Nplate
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Completion of participation in the study RMP-ITP-III while maintaining the clinical effectiveness of romiplostim therapy

Exclusion criteria

Exclusion Criteria:

  • to the components of the study drug or E. Coli proteins;
  • Pregnancy or breastfeeding;
  • Any diseases and conditions that, in the opinion of the Investigator, may hinder the patient's participation in the study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
160 participants (actual)

Study arms

  • Experimental
    GNR-069

    Weekly subcutaneous injections of GNR-069 in the individually titrated dose.

    Biological: GNR-069

Interventions

  • BiologicalGNR-069

    Once a week as a subcutaneous injection.

    Also known as: romiplostim

06

What researchers measure

Primary outcomes

  1. Frequency and severity of adverse events associated with the use of the GNR-069

    Adverse events will be assessed based on complaints, physical examination and laboratory data.

    Time frame: up to 29 weeks

  2. Number of undesirable events of particular interest in the study (Bleeding;Thrombotic/thromboembolic events)

    The event of particular interest in this study are bleeding and thrombotic/thromboembolic events of any location.

    Time frame: up to 29 weeks

  3. Number of clinically significant bleeding on Visits 1-5

    The clinically significant bleeding will be considered events ≥ grade 2 according to CTCAE 5.0.

    Time frame: up to 29 weeks

  4. Number and proportion of the patient with antidrug antibodies.

    The antidrug antibodies willl be characterized by their type, titer and neutralizing activity.

    Time frame: up to 29 weeks

Secondary outcomes

  1. Frequency of the loss of the treatment response

    Loss of the treatment response is assessed as absense of platelet increase ≥ 50,0 х 109/L on the 4 weeks treatment with maximal study drug dose.

    Time frame: up to 27 weeks

  2. Platelet count dynamics at Visits 1-5

    The platalets must be counted till week 5

    Time frame: up to 5 weeks

  3. Сhange in ITP-BAT bleeding scores from baseline to week 27

    ITP-specific bleeding assessment tool (ITP-BAT) will be calculated at baseline and at week 27.

    Time frame: up to 27 weeks

07

Study locations

13 sites
  • State Budgetary Institution of Healthcare Irkutsk awarded the "Sign of Honor" Order Regional Clinical Hospital
    Irkutsk, Irkutsk Region 664079, Russian Federation
  • State Budgetary Health Institution of the Kaluga Region "Kaluga Regional Clinical Hospital"
    Kaluga, Kaluga Region 248007, Russian Federation
  • State budgetary institution of health care of the Nizhny Novgorod region "Nizhny Novgorod Regional Clinical Hospital named after N. A. Semashko"
    Nizhny Novgorod, Nizhny Novgorod Region 603126, Russian Federation
  • Llc "Medis"
    Nizhny Novgorod, Nizhny Novgorod Region 603137, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Novosibirsk State Medical University" of the Ministry of Health of the Russian Federation
    Novosibirsk, Novosibirsk Region 630091, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Bashkir State Medical University" of the Ministry of Health of the Russian Federation
    Ufa, Republic Of Bashkortostan 450008, Russian Federation
  • Federal State Budgetary Educational Institution of Higher Education "Rostov State Medical University" of the Ministry of Health of the Russian Federation
    Rostov-on-Don, Rostov Region 344022, Russian Federation
  • State Health Institution of the Tula Region "Tula Regional Clinical Hospital"
    Tula, Tula Region 300053, Russian Federation
  • Municipal budgetary institution "Central City Hospital No. 7"
    Ekaterinburg, 620137, Russian Federation
  • State Budgetary Institution of Healthcare of the city of Moscow "Moscow Clinical Scientific and Practical Center named after A.S. Loginov" Department of Health of the city of Moscow
    Moscow, 111123, Russian Federation
  • Federal State Budget Funded Institution National Medical Research Center of Hematology, Ministry of Health of the Russian Federation (MoH of Russia)
    Moscow, 125167, Russian Federation
  • State budgetary health care institution of the city of Moscow "City Clinical Hospital named after V.V. Veresaev of the Department of Health of the City of Moscow"
    Moscow, 127644, Russian Federation
  • Federal State Budgetary Institution "National Medical Research Center named after V.A. Almazov" of the Ministry of Health of the Russian Federation
    Saint Petersburg, 191014, Russian Federation
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2022 to primary completion in Apr 2024, 24 months.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 24 months is close to that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 3, 2022
First posted
Aug 8, 2022
StartActual
Mar 28, 2022
Primary completionActual
Apr 3, 2024
CompletionActual
Apr 3, 2024
Last update
Jun 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05492409
Lead sponsor
AO GENERIUM
Responsible party
Sponsor
First posted
Aug 8, 2022
Start date
Mar 28, 2022
Primary completion
Apr 3, 2024
Completion
Apr 3, 2024
Last update
Jun 21, 2024

Study contacts

Oksana A. Markova, MD, MSc
study chair · AO GENERIUM

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Romiplostim

Start the discussion